[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ngs\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ngs":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,72,103,130,157],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100633874","integrating-tumor-genomics-and-urinary-exosomal-proteomics-to-establish-a-multi-layer-biomarker-framework-for-early-risk-stratification-and-post-treatment-surveillance-in-fresh-thyroid-cancer-patients-100633874",false,"NCT07532356","Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk Stratification and Post-Treatment Surveillance in Fresh Thyroid Cancer Patients","Inclusion Criteria:\n\n* Aged 18 to 80 years\n* Newly diagnosed Papillary Thyroid Carcinoma (PTC) or highly suspected follicular thyroid neoplasms (including lesions with potential progression to poorly differentiated thyroid carcinoma)\n* Pre-operative status\n\nExclusion Criteria:\n\n* Aged \\\u003C18 or \\>80 years\n* No confirmed diagnosis of Papillary Thyroid Carcinoma (PTC)\n* No highly suspected follicular thyroid neoplasms (including lesions with potential progression to poorly differentiated thyroid carcinoma)","ALL","18 Years","80 Years",{"count":19,"type":20},100,"ESTIMATED","3 Months","OBSERVATIONAL","Thyroid cancer is the most common endocrine malignancy, and although differentiated thyroid cancer (DTC) generally confers favorable outcomes, 10-20% of patients still face substantial postoperative risks, including local recurrence, distant metastasis, and inadequate response to radioactive iodine therapy. Current risk stratification, largely based on tumor size, lymph node involvement, and histopathology, fails to adequately represent tumor heterogeneity and evolutionary changes, potentially resulting in both overtreatment and undertreatment. Next-generation sequencing (NGS) has revealed a stepwise accumulation of genomic alterations from early driver mutations (e.g., BRAF, RAS, RET\u002FPTC, PAX8-PPARG) to late-stage progression events (e.g., TERT promoter, TP53, PI3K\u002FAKT\u002FmTOR), while metastatic lesions often harbor high-risk mutations absent in primary tumors, underscoring the limitations of single-time-point tissue sampling. Furthermore, serum thyroglobulin (Tg) surveillance is hindered in patients with anti-Tg antibodies. Extracellular vesicles (EVs), particularly those obtained from urine, provide a compelling liquid biopsy modality due to their non-invasiveness, repeatability, and reduced interference by abundant serum proteins. The investigators' previous findings demonstrate that urinary exosomal peptides-including U-Ex Tg, ANXA2, TIMP, and Angiopoietin-1-correlate with malignancy, capsular invasion, and nodal metastasis, and exhibit dynamic postoperative variation, suggesting their utility in detecting molecular residual disease.\n\nThis prospective study will recruit 100 fresh thyroid cancer cases and integrate tumor genomic profiling, urinary exosomal proteomics via LC-MRM\u002FMS, and clinical phenotype assessment-including nodal involvement, subsequent therapies, and long-term outcomes-to delineate causal links between genomic drivers, proteomic execution signals, and clinical progression. The overarching aim is to establish an early risk-stratification and molecular recurrence-alerting model capable of identifying high-risk trajectories earlier than conventional approaches, thereby enhancing surveillance precision and enabling timely intervention. This multi-layered biomarker framework holds strong potential to redefine postoperative monitoring standards and advance the clinical and policy implementation of precision medicine in thyroid cancer.",[25,26,27],"Genomics","Thyroid Cancer","NGS",[27,29,30,31,32],"Urinary exosomal peptides","Differentiated thyroid cancer","Molecular recurrence surveillance","Risk stratification","NOT_YET_RECRUITING","2026-04-15",{"date":36,"type":37},"2026-04-20","ACTUAL",{"date":39,"type":20},"2026-08-01",{"date":41,"type":20},"2031-07-31",{"name":43,"class":44},"National Taiwan University Hospital","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":5},"100593468","a-multicenter-prospective-blood-collection-study-in-a-kidney-transplant-population-100593468","NCT07006831","A Multicenter, Prospective Blood Collection Study in a Kidney Transplant Population","Accept cfDNA","Inclusion Criteria:\n\n1. Willing and able to provide written informed consent\n2. Is 18 years of age or older at enrollment\n3. Had a kidney transplant prior to enrollment\n4. Is having an indication (for cause) biopsy as determined by clinician\n5. retrospective leftover samples are available from the kidney donor(s).\n\nExclusion Criteria:\n\n1. Is pregnant\n2. Had a blood transfusion within the past 4 weeks\n3. Had a transplant from an identical (monozygotic) twin\n4. Had transplants of multiple organs from the same donor (eg, kidney and liver transplant).\n5. Had transplants of more than 2 organs from different donors (eg, recipient of a third kidney transplant)\n6. Had a transplant of hematopoietic stem cells (eg, bone marrow) or tissue (eg, heart valve)",{"count":53,"type":20},400,"The purpose of this research is to collect blood samples and data from kidney transplant patients. The samples and data will be used for research and development of non-invasive test to detect donor-derived cell-free DNA (dd-cfDNA) in kidney transplant patients to evaluate the status of the transplanted organ.",[56,57,58,59,60,27],"Kidney Disease","Kidney Transplant","Transplant Recipient","Renal Function","Cell-free DNA","RECRUITING","2025-12-15",{"date":64,"type":37},"2025-12-17",{"date":66,"type":37},"2025-11-14",{"date":68,"type":20},"2027-03",{"name":70,"class":71},"Devyser Inc.","INDUSTRY",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100604280","performance-indicators-and-impact-on-the-care-pathway-of-sequencing-on-the-seqoia-and-auragen-seqogen-platforms-for-oncology-patients-100604280","NCT07147465","Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology Patients","Indicateurs de Performance et Impact Sur le Parcours de Soins du Séquençage Sur Les Plateformes Seqoia et Auragen (Seqogen) Pour Les Patients en Oncologie","SONCO","Inclusion Criteria:\n\n* Patients diagnosed with cancer and referred for high-throughput sequencing\n* Sequencing pre-indication validated: Patients for whom the pre-indication for sequencing the genome, exome, and RNA has been validated by the upstream RCP (Multidisciplinary Tumor Board) since January 1, 2021.\n\nConsent for data reuse: Patients who have agreed to the reuse of their medical and genomic data for research purposes and have not opposed this use.\n\nExclusion Criteria:\n\n* Opposition to data reuse, unvalidated upstream RCP",{"count":81,"type":20},3149,"As part of the French Genomic Medicine Plan 2025 (FGM), the SeqOIA and AURAGEN platforms were selected to perform high-throughput genomic sequencing.\n\nThe SONCO (Sequencing Oncology Cohort) project combines their medical and economic evaluations into a single national cohort. Its objective is to assess the impact of genomic sequencing on care pathways and treatment recommendations by collecting indicators related to quality, turnaround time, and patient information. Clinical data are gathered from molecular tumor board reports (via SPICE and HYGEN) and from hospital medical records.\n\nThis cohort is intended to support public health decision-making and help anticipate the organization of future genomic platforms.",[84,27,85,86],"Cancer","Tumor","RARE DISEASE",[88,89,90,91,92],"Oncology","genomic medecine","cancer","rare diseases","next-generation sequencing","2025-08-22",{"date":95,"type":37},"2025-08-29",{"date":97,"type":37},"2025-07-01",{"date":99,"type":20},"2026-09-30",{"name":101,"class":44},"Assistance Publique - Hôpitaux de Paris",3,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":125,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},"100596450","primary-resistance-mechanisms-of-alk-tkis-100596450","NCT07045610","Primary Resistance Mechanisms of ALK TKIs","Explore the Primary Resistance Mechanisms of Anaplastic Lymphoma Kinase Inhibitors","Inclusion Criteria:\n\n1. Age ≥ 18 years old.\n2. Histologically or cytologically diagnosed NSCLC\n3. ALK gene fusion detected at initial diagnosis of NSCLC\n4. Patients exhibiting primary resistance to ALK-TKI therapy, defined as the absence of initial response or progression within 3 to 6 months of treatment initiation, were included.\n5. Able and willing to provide written informed consent prior to performing any study related procedures and to comply with the study protocol.\n\nExclusion Criteria:\n\n1. Unable to provide written inform consent\n2. The patients had received other systemic treatments except ALK TKI.\n3. Unable to undergo tumor biopsy or venipuncture",{"count":111,"type":20},20,"Anaplastic lymphoma kinase (ALK) gene rearrangement is a known oncogenic driver in non-small cell lung cancer (NSCLC). ALK tyrosine kinase inhibitors (TKIs) have been clearly shown to produce excellent therapeutic effects and prolong survival in patients with this gene mutation. According to current treatment guidelines, ALK inhibitors are the first-line treatment of choice for ALK-positive advanced NSCLC patients. However, although ALK TKIs are very effective, there is still a small group of patients who do not achieve good treatment outcomes, developing resistance and tumor progression within 3 to 6 months of initial ALK TKI use. This is called primary resistance. Intrinsic resistance to ALK inhibition occurs when the best clinical response after first-generation and second\u002Fthird-generation TKI treatment is disease progression. Approximately 5-7% of cases after crizotinib treatment, 9% after ceritinib treatment, and 25% after lorlatinib treatment show no response to treatment, and no specific ALK mutation has been found to explain the occurrence of primary resistance. Currently, many different resistance mechanisms are known, some of which are still ALK-related, while others are ALK-independent alternative survival pathways. However, most research focuses on acquired resistance, with very few studies on primary resistance, only a few case reports. Therefore, this study aims to explore the primary ALK TKI resistance mechanisms.\n\nThe investigators plan to explore the incidence and mechanisms of primary ALK TKI resistance in ALK-positive advanced NSCLC patients who develop primary resistance or rapid progression (within 3-6 months) during ALK inhibitor treatment by re-obtaining tumor samples for genetic analysis.",[114,115,27],"ALK-positive Advanced NSCLC Patients","Primary Resistance",[117,118,119,120,121,122],"lung cancer","Anaplastic lymphoma kinase (ALK) gene rearrangement","gene mutation","Primary resistance","Next-generation sequencing","Target therapy","2025-06-22",{"date":97,"type":37},{"date":97,"type":20},{"date":127,"type":20},"2028-07-01",{"name":43,"class":44},1,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":138,"phases":139,"briefSummary":141,"conditions":142,"keywords":145,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":129},"100572182","diagnostic-value-of-next-generation-sequencing-analysis-in-biliary-tract-tumours-100572182","NCT06729944","Diagnostic Value of Next-Generation Sequencing Analysis in Biliary Tract Tumours","Inclusion Criteria:\n\n* Availability of enough tissue for histological and NGS analysis (at least 20 ng DNA).\n* Age greater than\u002Fequal to 18 years.\n\nExclusion Criteria:\n\n* None",{"count":137,"type":20},50,"INTERVENTIONAL",[140],"NA","The aim of this study is to identify a dysplasia- and CCA-specific NGS panel to increase the diagnostic sensitivity of histological and\u002For cytological examination of biliary tract stenosis.",[143,27,144],"Hepatectomy","Stenosis of Bile Duct",[146,147],"Next Generation Sequencing","Stenosis of bile duct","2024-12-10",{"date":150,"type":37},"2024-12-12",{"date":152,"type":37},"2023-04-27",{"date":154,"type":20},"2026-06",{"name":156,"class":44},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":15,"minAge":164,"maxAge":165,"enrollmentInfo":166,"targetDuration":168,"studyType":22,"phases":4,"briefSummary":169,"conditions":170,"keywords":179,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":129},"100544681","tornado-omics-techniques-and-neural-networks-for-the-development-of-predictive-risk-models-100544681","NCT06372054","TORNADO-Omics Techniques and Neural Networks for the Development of Predictive Risk Models","Integration of Omics-based Technologies and Artificial Intelligence to Identify Predictive Risk Models in a Air Force's Pilot Cohort for the Maintenance of Safety, Well-being, Health, and Performance to be Translated to Civil Population","Inclusion Criteria:\n\n* Being part of the Italian Air Force, as in active flight service or ground staff\n* Age between 26 and 38 years\n* Consent to collect biological samples and use the wearable device to monitor exposure parameters\n\nExclusion Criteria:\n\n* Age \\\u003C 25 years and \\> 39 years\n* no signature on informed consent","26 Years","38 Years",{"count":167,"type":20},200,"3 Years","The goal of this observational study is to define a personalized risk model in the super healthy and homogeneous population of Italian Air Force high-performance pilots. This peculiar cohort conducts dynamic activities in an extreme environment, compared to a population of military people not involved in flight activity. The study integrates the analyses of biological samples (urine, blood, and saliva), clinical records, and occupational data collected at different time points and analyzed by omic-based approaches supported by Artificial Intelligence. Data resulting from the study will clarify many etiopathological mechanisms of diseases, allowing the creation of a model of analyses that can be extended to the civilian population and patient cohorts for the potentiation of precision and preventive medicine.",[171,172,173,174,175,176,177,178,27],"Oxidative Injury","Stress Physiological","Discogenic Pain","Cardiovascular Risk Factor","Space Maintenance","Epigenetic Changes","LONGEVITY 1","Neuroplasticity",[180,181,182,183],"pilots","air force","epigenetic change","environmental exposure","2024-04-16",{"date":186,"type":37},"2024-04-17",{"date":188,"type":37},"2024-02-05",{"date":190,"type":20},"2027-02-05",{"name":192,"class":44},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico"]